Ann: Epichem Awarded Major US Drug Discovery Contract Extension, page-2

7 June 2018 – Perth, Australia: PharmAust Limited (ASX : PAA), a clinical-stage oncology company, is pleased to announce that its wholly owned subsidiary, Epichem Pty Ltd, has been awarded an extension to its contract with a leading Californian biotechnology company, Unity Biotechnology, Inc. (“Unity”).

The contract will see Epichem continue to provide synthetic and medicinal chemistry expertise to support Unity’s drug discovery projects aimed at extending human health span.

The contract extension, until early-2020, is expected to generate up to US$1.65m in revenues for Epichem during this period.

Epichem’s CEO, Dr Martine Keenan said “We are delighted to continue working with Unity in such an exciting field of research. The Epichem team are looking forward to strengthening our relationship with the company to support this important work.”

PharmAust’s Chairman Dr Roger Aston said “It is exciting that Epichem have secured a meaningful extension to this work with such a leading contributor as Unity. This further demonstrates the significance of the expansion of the laboratory capacity at Epichem”